/Regeneron%20Pharmaceuticals%20logo%20is%20seen%20on%20a%20screen%20and%20a%20hand%20holding%20pills_%20By%20Rafael%20Henrique.jpeg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that turns cutting-edge science into medicines for some of the world’s most serious diseases. The company has a market capitalization of $85.3 billion, and its portfolio spans eye diseases, immunology and inflammation, cancer, cardiovascular and metabolic disorders, neurological conditions, and rare diseases, with key medicines including EYLEA, Dupixent, and Libtayo.
Regeneron has been on a tear over the past year, with the stock surging 45.6% and leaving the S&P 500 Index’s ($SPX) 18.7% return far behind. However, the momentum has cooled somewhat in 2026, with REGN up 8% year to date compared to the index’s 12.2% gain.
